Jyong Biotech Ltd. Ordinary Shares (MENS) - Total Liabilities
Based on the latest financial reports, Jyong Biotech Ltd. Ordinary Shares (MENS) has total liabilities worth $60.14 Million USD as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how efficiently does Jyong Biotech Ltd. Ordinary Shares generate cash to assess how effectively this company generates cash.
Jyong Biotech Ltd. Ordinary Shares - Total Liabilities Trend (2020–2024)
This chart illustrates how Jyong Biotech Ltd. Ordinary Shares's total liabilities have evolved over time, based on quarterly financial data. Check MENS asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Jyong Biotech Ltd. Ordinary Shares Competitors by Total Liabilities
The table below lists competitors of Jyong Biotech Ltd. Ordinary Shares ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ekovest Bhd
KLSE:8877
|
Malaysia | RM8.28 Billion |
|
Silicon Power Computer & Communications
TWO:4973
|
Taiwan | NT$1.00 Billion |
|
BV Financial, Inc. Common Stock
NASDAQ:BVFL
|
USA | $728.41 Million |
|
Guerbet S. A.
PA:GBT
|
France | €644.94 Million |
|
Taokaenoi Food & Marketing Public Company Limited
BK:TKN
|
Thailand | ฿1.92 Billion |
|
United Security Bancshares
NASDAQ:UBFO
|
USA | $1.11 Billion |
|
DNF Co.Ltd
KQ:092070
|
Korea | ₩8.13 Billion |
|
Bonei Hatichon Civil Engineering and Infrastructures Ltd
TA:BOTI
|
Israel | ILA1.25 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Jyong Biotech Ltd. Ordinary Shares's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Jyong Biotech Ltd. Ordinary Shares market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -2.68 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.60 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jyong Biotech Ltd. Ordinary Shares's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jyong Biotech Ltd. Ordinary Shares (2020–2024)
The table below shows the annual total liabilities of Jyong Biotech Ltd. Ordinary Shares from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $42.88 Million | +1.33% |
| 2023-12-31 | $42.32 Million | +10.28% |
| 2022-12-31 | $38.38 Million | +17.15% |
| 2021-12-31 | $32.76 Million | +2.22% |
| 2020-12-31 | $32.05 Million | -- |
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd., a science-driven biotechnology company, develops and commercializes plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops MCS-2 for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder … Read more